Goldman Sachs
FBLG icon

Goldman Sachs’s FibroBiologics FBLG Stock Holding History

Goldman Sachs’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-523
Closed -$2.35K – 7063
2025
Q4 		$2.35K Hold
523
– – ﹤0.01% 6397
2025
Q3 		$5.72K Sell
523
-6,054
-92% -$72.5K ﹤0.01% 6270
2025
Q2 		$81.8K Buy
6,577
+3,146
+92% +$56.7K ﹤0.01% 5854
2025
Q1 		$61.8K Buy
3,431
+202
+6% +$5.77K ﹤0.01% 5860
2024
Q4 		$129K Buy
3,229
+1,138
+54% +$61.1K ﹤0.01% 5718
2024
Q3 		$129K Buy
2,091
+1,450
+226% +$96.4K ﹤0.01% 5544
2024
Q2 		$64K Buy
+641
New +$122K ﹤0.01% 5449

Other funds holding FBLG

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

Goldman Sachs's FBLG Position: Q1 2026 in Review

Goldman Sachs sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 523 shares — an estimated $2.35K sold.

Goldman Sachs first reported a position in FBLG in Q2 2024 and held it in 7 quarters. The position peaked at $129K in Q3 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • Goldman Sachs reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
  • Goldman Sachs sold 523 FibroBiologics shares in Q1 2026, an estimated $2.35K.
  • Goldman Sachs first reported a position in FibroBiologics in Q2 2024 and held it in 7 quarters.
  • Goldman Sachs's FibroBiologics position peaked at $129K in Q3 2024.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.